Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer

Experimental and Therapeutic Medicine

Volumn 9, Issue 5, 2015, Pages 2003-2007

  Lu, Yaping ^a   Huang, Sen ^a   Li, Ping ^a   Chen, Bing Yu ^a   Liu, Wei Ling ^a   Chen, Zhi Qing ^a   Yin, Fubo ^b  

^a Department of Urology Haimen City People's Hospital   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

C reactive protein; Cancer antigen 125; Clinicopathological data; Epithelial ovarian cancer; Prognosis

Indexed keywords

C REACTIVE PROTEIN; CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; ASCITES; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CELL CYCLE PHASE; CHEMOLUMINESCENCE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PREOPERATIVE CARE; PROTEIN EXPRESSION; SURVIVAL RATE;

EID: 84925047857     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2350     Document Type: Article

References (34)

1. Wong KH, Mang OW, Au KH and Law SC:. Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. Hong Kong Med J 18: 466-474, 2012.
2. Helzlsouer KJ, Erlinger TP and Platz EA: C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer 42: 704-707, 2006.
3. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
4. Hefler LA, Zeillinger R, Grimm C, et al: Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 103: 512-517, 2006.
5. Tempfer C, Zeisler H, Sliutz G, et al: Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 66: 27-30, 1997.
6. Zeimet AG, Widschwendter M, Knabbe C, et al: Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 16: 1861-1868, 1998.
7. Friedlander ML: Prognostic factors in ovarian cancer. Semin Oncol 25: 305-314, 1998.
8. Winter-Roach BA, Kitchener HC and Lawrie TA: Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 3: CD004706, 2012.
9. Marchetti C1, Pisano C, Facchini G, et al: First-line treatment of advanced ovarian cancer: current research and perspectives. Expert Rev Anticancer Ther 10: 47-60, 2010.
10. Marnell L, Mold C and Du Clos TW: C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117: 104-111, 2005.
11. Allavena P, Garlanda C, Borrello MG, Sica A and Mantovani A: Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18: 3-10, 2008.
12. Lundin E, Dossus L, Clendenen T, et al: C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control 20: 1151-1159, 2009.
13. Siemes C, Visser LE, Coebergh JW, et al: C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 24: 5216-5222, 2006.
14. Il'yasova D, Colbert LH, Harris TB, et al: Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14: 2413-2418, 2005.
15. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A and Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15: 381-384, 2006.
16. Gockel I, Dirksen K, Messow CM and Junginger T: Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 12: 3746-3750, 2006.
17. Hashimoto K, Ikeda Y, Korenaga D, et al: The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 103: 1856-1864, 2005.
18. McMillan DC, Canna K and McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90: 215-219, 2003.
19. Brown DJ, Milroy R, Preston T and McMillan DC: The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol 60: 705-708, 2007.
20. Polterauer S, Grimm C, Tempfer C, et al: C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 107: 114-117, 2007.
21. Anastasi E, Marchei GG, Viggiani V, et al: HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 31: 113-119, 2010.
22. Klug TL, Bast RC Jr, Niloff JM Knapp RC and Zurawski VR Jr: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 44: 1048-1053, 1984.
23. Schilthuis MS, Aalders JG, Bouma J, et al: Serum CA 125 levels in epithelial ovarian cancer: relation with findings at second-look operations and their role in the detection of tumour recurrence. Br J Obstet Gynaecol 94: 202-207, 1987.
24. Santillan A, Garg R, Zahurak ML, et al: Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 23: 9338-9343, 2005.
25. Howe HL, Tung KH, Coughlin S, Jean-Baptiste R and Hotes J: Race/ethnic variations in ovarian cancer mortality in the United States, 1992-1997. Cancer 97 (10 Suppl): 2686-2693, 2003.
26. Benedet JL, Bender H, Jones H III, Ngan HY and Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70: 209-262, 2000.
27. McSorley MA, Alberg AJ, Allen DS, et al: C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 109: 933-941, 2007.
28. Ness RB: Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189: 280-294, 2003.
29. Tung KH, Wilkens LR, Wu AH, et al: Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 161: 321-329, 2005.
30. Shacter E and Weitzman SA: Chronic inflammation and cancer. Oncology (Williston Park) 16: 217-226, 2002.
31. McMillan DC, Elahi MM, Sattar N, et al: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41: 64-69, 2001.
32. Hefler LA, Concin N, Hofstetter G, et al: Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 14: 710-714, 2008.
33. Hefler-Frischmuth K, Hefler LA, Heinze G, et al: Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol 147: 65-68, 2009.
34. Lu Y, Yin F and Chen Z: Prognostic value of preoperative serum C-reactive protein in patients with epithelial ovarian cancer. Progress in Obstetrics and Gynecology 17: 489-492, 2008.